Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
This news is really alarming that resistance has developed to two drug Artemisinin Combination Therapy (ACT) because of high treatment failure rates to a widely used frontline malaria drug combination—dihydroartemisinin-piperaquine (DHA-PPQ) in Cambodia, Vietnam, etc.
ACT consists of an artemisinin derivative combined with a long acting antimalarial (amodiaquine, lumefantrine, mefloquine or sulfadoxine-pyrimethamine). The ACT used in the national programme in India is artesunate + sulfadoxine-pyrimethamine combination. Our suggestion is that 3-drug treatment instead of 2 drug treatment as in India should be used instead.